Medco Research's Adenocard (adenosine)
Executive Summary
Medco Research's Adenocard (adenosine): Has received "approvable" status from FDA, the company announced Oct. 26, adding that it hopes to receive final approval in November. The injectable anti-arrhythmic product would be approved for I.V. treatment of paroxysmal supraventricular tachycardia in a hospital setting. Medco has licensed the drug to Fujisawa (Lyphomed) for marketing in the U.S. and to Sanofi for marketing outside North America. The drug was recommended for approval by FDA's Cardio-Renal Drugs Advisory Committee on May 4 ("The Pink Sheet" May 8, p. 7). The company is developing the drug for at least seven other indications.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.